![Thomas Barnes](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas Barnes
Director/Miembro de la Junta en Orna Therapeutics, Inc. .
Perfil
Thomas M.
Barnes is currently the Director at Orna Therapeutics, Inc. and the Executive Partner at MPM BioImpact, Inc. He previously worked as the Director-Genomic Pharmacology at Millennium Pharmaceuticals, Inc., Senior Vice President-Discovery at Ore Pharmaceuticals, Inc., Vice President-Discovery at Sesen Bio, Inc., and Senior VP-Innovative Sciences & eXtellia at Intellia Therapeutics, Inc. He holds a doctorate degree from the University of Cambridge, which he obtained in 1991, and an undergraduate degree from The University of Sydney, which he obtained in 1981.
Cargos activos de Thomas Barnes
Empresas | Cargo | Inicio |
---|---|---|
Orna Therapeutics, Inc.
![]() Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Director/Miembro de la Junta | - |
MPM BioImpact, Inc
![]() MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Inversor de Capital Privado | 01/02/2020 |
Antiguos cargos conocidos de Thomas Barnes.
Empresas | Cargo | Fin |
---|---|---|
CARISMA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2013 |
INTELLIA THERAPEUTICS, INC. | Director Técnico/Científico/I+D | - |
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Ore Pharmaceuticals, Inc.
![]() Ore Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ore Pharmaceuticals, Inc. operates as a drug development company, which developed drug candidates for therapeutic uses. The firm marketed its drug repositioning capabilities to pharmaceutical companies based in North America, Japan and Europe. The company was founded in September 1994 and was headquartered in Wellesley, MA. | Corporate Officer/Principal | - |
Formación de Thomas Barnes.
University of Cambridge | Doctorate Degree |
The University of Sydney | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
INTELLIA THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 5 |
---|---|
Ore Pharmaceuticals, Inc.
![]() Ore Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ore Pharmaceuticals, Inc. operates as a drug development company, which developed drug candidates for therapeutic uses. The firm marketed its drug repositioning capabilities to pharmaceutical companies based in North America, Japan and Europe. The company was founded in September 1994 and was headquartered in Wellesley, MA. | Health Technology |
Sesen Bio, Inc.
![]() Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Orna Therapeutics, Inc.
![]() Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Health Technology |
MPM BioImpact, Inc
![]() MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
- Bolsa de valores
- Insiders
- Thomas Barnes